EPS for IntelGenx Technologies Corp. (IGX) Expected At $-0.05

July 14, 2018 - By Patrick Harkless

IntelGenx Technologies Corp. (CVE:IGX) Logo

Analysts expect IntelGenx Technologies Corp. (CVE:IGX) to report $-0.05 EPS on August, 9.They anticipate $0.04 EPS change or 400.00 % from last quarter’s $-0.01 EPS. After having $-0.04 EPS previously, IntelGenx Technologies Corp.’s analysts see 25.00 % EPS growth. The stock decreased 0.99% or $0.01 during the last trading session, reaching $0.99. About 10,083 shares traded or 23.28% up from the average. IntelGenx Technologies Corp. (CVE:IGX) has 0.00% since July 14, 2017 and is . It has underperformed by 12.57% the S&P500.

IntelGenx Technologies Corp., a drug delivery company, develops novel oral immediate-release and controlled-release products for the pharmaceutical market. The company has market cap of $70.49 million. It offers RIZAPORT, an oral thin film formulation of rizatriptan benzoate for the treatment of acute migraines. It currently has negative earnings. The company's products under development comprise INT0001/2004, an anti-hypertension drug; INT0004/2006, an antidepressant; INT0007/2006 for the treatment of erectile dysfunction; INT0010/2006 for the treatment of neuropathic pain and nausea in cancer patients; INT0027/2011 to treat opioid dependence; INT0036/2012 for schizophrenia; and INT0043/2015 to treat mild cognitive impairment and Alzheimer's disease.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.